The global automated and closed cell therapy processing system market size surpassed USD 1,530 million in 2024 and is predicted to reach around USD 12,630 million by 2034, registering a CAGR of 23.5% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 1,890 Million |
| Market Size by 2034 | USD 12,630 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 23.5% |
The actual revolution in cell therapy manufacturing has come to the pharmaceutical industry through an increasing ability to leverage increased precision, safety, and scale. The cell therapy manufacturing processes, only selection, isolation, modification, and expansion-are highly complicated, in which the slightest variation may result in a final product of poor quality. Negative impact on quality has been minimized by automated and closed systems that render therapeutic cells safe and correct during their infusion.
Minimizing manual operations results in a reduced chance of contaminating cell therapy products and improving the overall consistency thereof. Biological processing is no longer reliable or cost-effective for scaling up of cell operations, thus reducing contamination.
As the world's burden of cancer and other challenging illnesses is increasing, such changes in market dynamics are also creating a strong demand for next-generation systems' high-performance solutions. The top companies also keep investing in and launching next-generation cell therapy manufacturing platforms to intensify the effectiveness and safety of cell therapy manufacturing, which would further augment market growth.
“Cellular Origins has developed Constellation to enable fully industrialised manufacture of cell and gene therapies.”
“The goal is to establish a seamlessly automated, plug-and-play process that positively influences patient care. The ongoing partnership with Thermo Fisher plays a crucial role in turning this vision into reality, advancing the realization of cell therapy for the benefit of patients.”
Regional factors dictate the development of the Automated and Closed Cell Therapy Processing System Market in Asia Pacific, North America, and Europe, and hence the rapid growth of this particular market in these regions.
North America
North America is the leading area for the global automated and closed cell therapy processing systems market. The fast acceptance of automated advanced manufacturing technologies in cell therapy has created a strong market presence in the region. In addition, the heavy concentration of research institutions and investment in the biotechnology and pharmaceutical sectors is further pushing the market in North America. The efforts made by major players have prompted much of the advancement in the automated and closed systems of that region.
Europe
Europe seems set for reasonable growth for automated and closed cell therapy processing systems. The reason behind such growth includes the presence of a well-built pharmaceutical industry, further boosted through research and development activities in biotechnology. The demand for personalized medicines is also expected to take the show forward in this region.
APAC
Asia Pacific is becoming one of the crucial markets for automated and closed cell therapy processing systems. Strong pharmaceutical industry growth opportunities in India, Japan, China, and South Korea drive market development. Increased emphasis will be placed on the development of medicines and automation during cell therapy manufacturing processes.
The Automated and Closed Cell Therapy Processing System Market is very fragmented, with leading companies such as Lonza, ThermoGenesis Holdings Inc., Sortorius, Cellares, Cytiva, BioSpherix, and Thermo Fisher Scientific Inc. The global Automated And Closed Cell Therapy Processing System Market is facing intense competition due to innovation, evolving consumer preferences, and product development, with brand managers focusing on global market share and differentiation.
The market is dominated by several companies renowned for their significant contributions. Based on recent data, the top three companies are:
In 2024, Sartorius AG, a German company operating in the life science industry, achieved a sales revenue of €3.4 billion. This represents a slight increase of +0.1% compared to the previous year.
BioSpherix's estimated annual revenue is currently $5.7M per year.
ThermoGenesis Holdings Inc.'s revenue for the relevant period is $9.61 million, with a cost of revenue of $7.58 million, resulting in a gross profit of $2.0 million.
Published by Ajit Bansod
